News

Austria’s new Federal Minister of Education, Science and Research, Martin Polaschek, visited the Vienna BioCenter on 24 March 2022. Stops at the IMP,…

17 Mar'22

VBC Group Leaders Andrea Pauli (IMP) and Yasin Dagdas (GMI). ©GMI/IMP/VBC

Andrea Pauli (IMP) and Yasin Dagdas (GMI) are each awarded a Consolidator Grant from the European Research Council (ERC). The two group leaders will…

08 Mar'22

Valneva announced the successful completion of the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553.

08 Mar'22

The Max Perutz Labs recognize the most ambitious and innovative PhD projects at the institute with the Max Perutz PhD Fellowship. This year’s winners…

07 Mar'22

Nonsense mediated mRNA decay (NMD) is a cellular surveillance mechanism that detects and degrades potentially dangerous mRNA transcripts containing…

04 Mar'22

Congratulations to group leader Kristin Tessmar-Raible who has received the oldest and highest award of the Austrian Academy of Sciences, the Ignaz…

02 Mar'22

Interleukin 1 alpha (IL-1α) and Interleukin 1 beta (IL-1β) are signaling molecules that regulate inflammation and immunity in response to infection.…

01 Mar'22

Valneva announced that the National Health Regulatory Authority (NHRA) of the Kingdom of Bahrain has granted emergency use authorization for Valneva’s…

26 Feb'22

Eveliqure Biotechnologies GmbH announced the publication of positive Phase I data with ShigETEC, its vaccine candidate against Shigellae and…

25 Feb'22

Valneva announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has provided an initial…

22 Feb'22

Congratulations to group leader Peter Schlögelhofer, who has been promoted to full professor by the University of Vienna. Using the model plant…

21 Feb'22

Valneva announced that its subsidiary Valneva Scotland has been awarded research and development funding of up to £20 million by Scottish Enterprise.

…

Minister of Education, Science and Research visits Vienna BioCenter

ERC Consolidator Grants for Andrea Pauli and Yasin Dagdas

Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

Max Perutz PhD Fellowships awarded

Cell fate determination: making sense out of nonsense

Ignaz Lieben Prize awarded to Kristin Tessmar-Raible

Resistance and tolerance: two sides of the same coin

Valneva Receives Emergency Use Authorization from Bahrain for its Inactivated COVID-19 Vaccine VLA2001

Eveliqure announces the publication of positive Phase I clinical data for its vaccine candidate against Shigellosis and ETEC

Valneva Receives Initial CHMP Assessment of its Inactivated, Adjuvanted COVID-19 Vaccine Candidate VLA2001

Peter Schlögelhofer promoted to University Professor

Valneva Awarded Up to £20 Million by Scottish Enterprise to Advance Vaccine Development